Immunic (IMUX) shares rose more than 14% in premarket trading after it reported "positive" outcomes from an interim analysis of its phase 3 trial of vidofludimus calcium for the treatment of relapsing multiple sclerosis.
Based on the interim analysis, an independent data monitoring committee has recommended that the trials should continue as planned. Completion is expected in 2026.
The trial includes two identical multicenter, randomized, double-blind phase 3 trials enrolling about 1,050 each designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in relapsing multiple sclerosis patients.
The primary endpoint for both trials is time to first relapse in up to 72 weeks. Secondary endpoints include time to worsening of disability.
Price: 1.8000, Change: +0.25, Percent Change: +16.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。